WATCH NOW: Optimizing Solid Tumor Management with PARP Inhibition

PARP Inhibitor Combination Regimens for Prostate Cancer ManagementПодробнее

Target Practice: Understanding How PARP Inhibitors Take Aim at DDR Mutations Across Solid TumorsПодробнее

Identifying Mutations and Optimizing Use of PARP InhibitorsПодробнее

INTERNATIONAL CONFERENCE ON CANCER SCREENING AND MANAGEMENT IN THE TRANSGENDER POPULATIONПодробнее

Mechanisms of PARP Inhibition: A Mode of Targeted Cancer TreatmentПодробнее

Optimizing the Use of PARP Inhibitors in Ovarian CancerПодробнее

Choosing the correct PARP inhibitor for prostate cancerПодробнее

Optimizing the management of patients with solid tumorsПодробнее

Ready for Prime Time? Determining the Current and Future Role of PARP Inhibitor-Based Combination...Подробнее

Updates in PARP inhibition for ovarian cancerПодробнее

The Future Role of PARP Inhibition in Ovarian CancerПодробнее

Managed Care Implications of the Expanding Role of PARP Inhibitors in OncologyПодробнее

PARP Inhibitors Treatment Update - Summit 2021Подробнее

BRCA+ Pancreatic Cancer Maintenance Debate: PARP Inhibitor or Continued Chemo? - PARP InhibitorПодробнее

The Role of Targeting DNA Repair with PARPПодробнее

Barriers to PARP Inhibitors Plus Androgen Receptor-Targeted Agents in Earlier Treatment SettingsПодробнее

Expanding the Benefits of PARP Inhibitors to More Patients With Breast Cancer and Earlier SettingsПодробнее

JAVELIN PARP Medley: Combining PARP inhibitors and immune checkpoint inhibitorsПодробнее

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее